Class Action Reports

SPPI Class Action: Learn About the Spectrum Pharmaceuticals Lawsuit

Levi & Korsinsky, LLP

September 3, 2021

Levi & Korsinsky, LLP announces that an SPPI class action lawsuit has been filed on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (SPPI) securities between December 27, 2018, and August 5, 2021 For more on the SPPI Lawsuit please contact us today.

 

Levi & Korsinsky

 

According to the Spectrum Pharmaceuticals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the ROLONTIS, an investigational granulocyte-colony stimulating factor analogue, manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application (“BLA”) in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

 

TO LEARN MORE ABOUT THE SPPI CLASS ACTION LAWSUIT, CLICK HERE

 

If you suffered a loss in Spectrum Pharmaceuticals you have until November 1, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

 

 

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com